Proceeds will expand late-stage clinical development of lead programme visugromab’s into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications Round brings on board new international biotech investors Gilde Healthcare, Canaan Partners, Bioqube Ventures, Omega Funds and Forbion Growth Fund to support direct path towards registration for visugromab CatalYm today announced...